Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening
Authors' conclusion
The established PDOs, retaining typical features of parental tumors, indicate a translational significance in innovating personalized treatment for refractory PitNETs.
Study context
- Population
- Patients with pathologically confirmed pituitary neuroendocrine tumors (PitNETs), Sun Yat-Sen University Cancer Center, July 2019 to May 2022
- Participants
- 32 PitNET specimens
- Outcome
- PDOs retained key genetic and morphological features of their parental tumors
Methodological detailssingle-centre, patient-derived organoids
- Single-centre
- Patient-derived organoids
Main finding
As reported in the abstract
Overall success rate of PDO establishment
87.5%
Success in clinical nonfunctioning PitNET-derived organoids
22/23, 95.7%
Success in functioning PitNET-derived organoids
6/9, 66.7%
Further findings
Drug response assay
- Distinctive drug response profile among organoids from different PitNET subtypes
- Patient-derived organoids (PDOs) showed predictive value in testing individual drugs
Original publication
Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening. J Clin Endocrinol Metab. Published 24 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →